237 related articles for article (PubMed ID: 8016872)
41. Differential effects of costimulatory pathway modulation on corneal allograft survival.
Watson MP; George AJ; Larkin DF
Invest Ophthalmol Vis Sci; 2006 Aug; 47(8):3417-22. PubMed ID: 16877411
[TBL] [Abstract][Full Text] [Related]
42. CTLA4-Ig-modified dendritic cells inhibit lymphocyte-mediated alloimmune responses and prolong the islet graft survival in mice.
Yang DF; Qiu WH; Zhu HF; Lei P; Wen X; Dai H; Zhou W; Shen GX
Transpl Immunol; 2008 Jul; 19(3-4):197-201. PubMed ID: 18667318
[TBL] [Abstract][Full Text] [Related]
43. Interleukin-6 receptor signaling disruption prevents cardiac allograft deterioration in mice.
Iida S; Omoto K; Kanemitsu I; Setoguchi K; Ishida H; Tanabe K; Suzuki T; Tashiro Y; Kishimoto H; Abe R
Exp Clin Transplant; 2012 Aug; 10(4):375-85. PubMed ID: 22758208
[TBL] [Abstract][Full Text] [Related]
44. Anergic cells induced by the blockade of CD40-CD154 and CD28-B7 costimulatory pathways act as potent immunoregulatory cells in vitro and vivo.
Cai Y; Zhou PJ; Tang XD
Chin Med J (Engl); 2004 Aug; 117(8):1178-83. PubMed ID: 15361291
[TBL] [Abstract][Full Text] [Related]
45. CD28-B7 T cell costimulatory blockade by CTLA4Ig in sensitized rat recipients: induction of transplantation tolerance in association with depressed cell-mediated and humoral immune responses.
Onodera K; Chandraker A; Schaub M; Stadlbauer TH; Korom S; Peach R; Linsley PS; Sayegh MH; Kupiec-Weglinski JW
J Immunol; 1997 Aug; 159(4):1711-7. PubMed ID: 9257832
[TBL] [Abstract][Full Text] [Related]
46. Prolongation of corneal allograft survival by CTLA4-FasL in a murine model.
Shi W; Chen M; Xie L
Graefes Arch Clin Exp Ophthalmol; 2007 Nov; 245(11):1691-7. PubMed ID: 17541621
[TBL] [Abstract][Full Text] [Related]
47. Donor antigen is necessary for the prevention of chronic rejection in CTLA4Ig-treated murine cardiac allograft recipients.
Sayegh MH; Zheng XG; Magee C; Hancock WW; Turka LA
Transplantation; 1997 Dec; 64(12):1646-50. PubMed ID: 9422396
[TBL] [Abstract][Full Text] [Related]
48. Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4(+) T cells, interferon-gamma, and CTLA4.
Markees TG; Phillips NE; Gordon EJ; Noelle RJ; Shultz LD; Mordes JP; Greiner DL; Rossini AA
J Clin Invest; 1998 Jun; 101(11):2446-55. PubMed ID: 9616216
[TBL] [Abstract][Full Text] [Related]
49. Mechanisms of targeting CD28 by a signaling monoclonal antibody in acute and chronic allograft rejection.
Dong VM; Yuan X; Coito AJ; Waaga AM; Sayegh MH; Chandraker A
Transplantation; 2002 Apr; 73(8):1310-7. PubMed ID: 11981427
[TBL] [Abstract][Full Text] [Related]
50. Blockade of the B7-CD28 pathway by CTLA4-Ig counteracts rejection and prolongs survival in small bowel transplantation.
Kurlberg G; Haglind E; Schön K; Törnqvist H; Lycke N
Scand J Immunol; 2000 Mar; 51(3):224-30. PubMed ID: 10736090
[TBL] [Abstract][Full Text] [Related]
51. Efficient myoblast transplantation in mice immunosuppressed with monoclonal antibodies and CTLA4 Ig.
Guérette B; Wood K; Roy R; Tremblay JP
Transplant Proc; 1997 Jun; 29(4):1932-4. PubMed ID: 9193460
[No Abstract] [Full Text] [Related]
52. Acute graft-versus-host reaction can be aborted by blockade of costimulatory molecules.
Hakim FT; Cepeda R; Gray GS; June CH; Abe R
J Immunol; 1995 Aug; 155(4):1757-66. PubMed ID: 7636232
[TBL] [Abstract][Full Text] [Related]
53. CTLA4-Ig: a novel immunosuppressive agent.
Najafian N; Sayegh MH
Expert Opin Investig Drugs; 2000 Sep; 9(9):2147-57. PubMed ID: 11060799
[TBL] [Abstract][Full Text] [Related]
54. Analysis of the B7 costimulatory pathway in allograft rejection.
Pearson TC; Alexander DZ; Corbascio M; Hendrix R; Ritchie SC; Linsley PS; Faherty D; Larsen CP
Transplantation; 1997 May; 63(10):1463-9. PubMed ID: 9175811
[TBL] [Abstract][Full Text] [Related]
55. Transplantation of islets transduced with CTLA4-Ig and TGFbeta using adenovirus and lentivirus vectors.
Fernandes JR; Duvivier-Kali VF; Keegan M; Hollister-Lock J; Omer A; Su S; Bonner-Weir S; Feng S; Lee JS; Mulligan RC; Weir GC
Transpl Immunol; 2004 Nov; 13(3):191-200. PubMed ID: 15381202
[TBL] [Abstract][Full Text] [Related]
56. Use of CTLA4-Ig in combination with conventional immunosuppressive agents to prolong allograft survival.
Hale DA; Gottschalk R; Maki T; Monaco AP
Transplantation; 1997 Sep; 64(6):897-900. PubMed ID: 9326417
[TBL] [Abstract][Full Text] [Related]
57. A clinically relevant CTLA4-Ig-based regimen induces chimerism and tolerance to heart grafts.
Li S; Thanikachalam M; Pang M; Kawaharada N; Aitouche A; Pham SM
Ann Thorac Surg; 2001 Oct; 72(4):1306-10. PubMed ID: 11603451
[TBL] [Abstract][Full Text] [Related]
58. Prolongation of skin allograft survival in mice treated with CTLA-4 Ig in combination with rapamycin or cyclosporine.
Hale DA; Gottschalk R; Wood ML; Maki T; Monaco AP
Transplant Proc; 1996 Dec; 28(6):3270-1. PubMed ID: 8962270
[No Abstract] [Full Text] [Related]
59. Apoptosis of peripheral T cells in rodent cardiac allograft recipients induced by donor-specific transfusion with impaired inducible costimulator/B7 homologous protein allorecognition.
Du JF; Shen XF; Ji XQ; Chen G; Bai X; Zuo FY; Yu B
Transplant Proc; 2013 Mar; 45(2):564-8. PubMed ID: 23498793
[TBL] [Abstract][Full Text] [Related]
60. In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice.
Blazar BR; Taylor PA; Linsley PS; Vallera DA
Blood; 1994 Jun; 83(12):3815-25. PubMed ID: 7515723
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
